- The European Commission approves AstraZeneca's (NYSE:AZN) Kyntheum (brodalumab) for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.
- Brodalumab is a biologic that selectively targets the interleukin-17 (IL-17) receptor subunit A, located on skin cells. Other interleukin inhibitors target free inflammatory mediators.
- LEO Pharma has exclusive commercialization rights in Europe. Valeant Pharmaceuticals has global commercial rights ex-Europe except Japan and certain other Asian countries where Kyowa Hakko Kirin Co. owns the rights.
- Brodalumab is marketed in the U.S. by Valeant under the brand name Siliq.